___

• 1. Kloner RA, Carson C 3rd, Dobs A, Kopecky S, Mohler ER 3rd. Testosterone and Cardiovascular Disease. J Am Coll Cardiol 2016;67:545–57. doi: 10.1016/j.jacc.2015.12.005
• 2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833–76. doi: 10.1210/er.2004-0013
• 3. Mulligan T, Frick M, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–9. doi: 10.1111/j.1742- 1241.2006.00992.x
• 4. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010;33:1186–92. doi: 10.2337/dc09-1649
• 5. Morgentaler A. Controversies and Advances with Testosterone Therapy: A 40-Year Perspective. Urology 2016;89:27–32. doi: 10.1016/j.urology.2015.11.034
• 6. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–22. doi: 10.1056/ NEJMoa1000485
• 7. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829–36. doi: 10.1001/ jama.2013.280386
• 8. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and metaanalysis of placebo-controlled randomized trials. BMC Med 2013;11:108. doi: 10.1186/1741-7015-11-108
• 9. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805. doi: 10.1371/journal.pone.0085805
• 10. Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med 2015;175:1187–96. doi: 10.1001/ jamainternmed.2015.1573
• 11. Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med 2014;11:624–9. doi: 10.1111/jsm.12464
• 12. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 2014;17:63–5. doi: 10.3109/13685538.2014.913413
• 13. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 2015;90:224–51. doi: 10.1016/j. mayocp.2014.10.011
• 14. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 1986;6:807–13.
• 15. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–8. doi: 10.1210/jc.2011-2591
• 16. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725–33. doi: 10.1530/EJE13-0321
• 17. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327–51. doi: 10.1517/14740338.2014.950653
• 18. Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone Replacement Therapy and Cardiovascular Risk: A Review. World J Mens Health 2015;33:130–42. doi: 10.5534/ wjmh.2015.33.3.130
• 19. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol 2016;8:147–60. doi: 10.1177/1756287215617648
• 20. Bhatt K, Johnson J. Summary Minutes of the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting, September 18, 2014. U. S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: https:// wayback.archive-it.org/7993/20170113050249/http://www. gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM424069.pdf Accessed December 2, 2015.
• 21. U. S. Food and Drug Administration 2015. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm436259. htm Accessed December 2, 2015.
• 22. Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement of the Association of Testosterone and Cardiovascular Risk. Endocr Pract 2015;21:1066–73. doi: 10.4158/EP14434.PS